trending Market Intelligence /marketintelligence/en/news-insights/trending/ZYOUNUhCF8lsqKWwYEbgrg2 content esgSubNav
In This List

Liquidia Technologies prices $34.5M common stock offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Liquidia Technologies prices $34.5M common stock offering

Liquidia Technologies Inc. priced an underwritten public offering of 3 million common shares at $11.50 apiece to raise $34.5 million in gross proceeds.

The biopharmaceutical company has also granted underwriters an option to buy up to an additional 450,000 shares.

Morrisville, N.C.-based Liquidia expects to close the offering March 25, subject to closing conditions.

Jefferies and Cowen are the joint book-running managers, with Needham & Co. and Wedbush PacGrow as co-managers for the offering.

Liquidia develops human therapeutics using its proprietary print technology, a particle engineering platform. Its lead product candidate LIQ861 — an inhaled dry powder formulation of treprostinil — is in a phase 3 study to treat pulmonary arterial hypertension.